An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors

Clinical trial NCT02038673 · COMPLETED

Trial details

NCT number

NCT02038673

Sponsor

Astellas Pharma Inc

Status

COMPLETED

Phase

Phase 1

Study type

INTERVENTIONAL

Start date

2013-11-05

Primary completion

2017-07-19

Enrollment

86

View on ClinicalTrials.gov